# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announ...
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies...
In accordance with Listing Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a period of 180 calendar days from t...